Cabaletta Bio, Inc.
CABA evidence brief
What we can confirm
- BioSniper Score:
- 8.0 / 10
- Market Cap:
- $554.4M
- Lead Asset:
- CABA-201 (Phase 2/Phase 3)
What it means
What to watch
Prepared research question
What matters most for CABA—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · CABA
Cabaletta Bio (CABA) is a publicly traded biotechnology company developing rese-cel, a CD19-directed CAR T-cell therapy for autoimmune diseases, with registrational programs in myositis and systemic sclerosis and a cash position of $225.1M as of June 30, 2026.
Key risk: Single-arm registrational data
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Financial data as of Jun 30, 2026.
Tracking 3 pipeline candidates · 7 clinical trials for Cabaletta Bio, Inc..
Cabaletta Bio (CABA) is a publicly traded biotechnology company developing rese-cel, a CD19-directed CAR T-cell therapy for autoimmune diseases, with registrational programs in myositis and systemic sclerosis and a cash position of $225.1M as of June 30, 2026.
- Lead candidate rese-cel (resecabtagene autoleucel) is a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T construct designed to deplete CD19-positive B cells [pipeline].
- Cash and equivalents were $225.1M as of June 30, 2026 [sec].
- Net loss was -$51.0M for the period ending June 30, 2026 [sec].
- Registrational RESET-Myositis data expected mid-2027 to support a BLA submission in the second half of 2027 [news · published 2026-08-13].
- A single-arm registrational study for systemic sclerosis (RESET-SSc) of approximately 25 patients is anticipated to initiate in the fourth quarter of 2026 [sec · filed 2026-06-03].
What works
- Rese-cel has shown potentially transformative, drug-free clinical responses with a favorable safety profile supporting outpatient use in autoimmune patients [news · published 2025-11-10].
- All myositis patients in the Phase 1/2 DM/ASyS cohort with sufficient follow-up who met key criteria for the registrational cohort met the 16-week primary endpoint [news · published 2025-11-10].
- The company has a substantial cash position of $225.1M as of June 30, 2026, providing runway for ongoing clinical programs [sec].
What to weigh
- The company reported a net loss of -$51.0M for the period ending June 30, 2026, reflecting high R&D and operational costs [sec].
- Cabaletta faces numerous risks and uncertainties in research, development, and commercialization, including the inability to estimate exact operating capital requirements [sec_mda · as of 2026-08-13].
- The registrational DM/ASyS cohort is based on a single-arm, 14-patient study, which may raise regulatory scrutiny regarding efficacy and safety [news · published 2025-11-10].
From the filings
Quoted directly from source documents.
Registrational SSc study initiation timeline
“Initiate SSc registrational program with preconditioning in 4Q26”
SEC filings · June 3, 2026
All myositis patients meeting registrational endpoint
“All myositis patients in the Phase 1/2 DM/ASyS cohort with sufficient follow-up who would have met key criteria for the registrational cohort met the registrational, 16-week primary endpoint”
News · November 10, 2025
Risks & what to watch (3)›
Key risks
- Single-arm registrational data — The DM/ASyS BLA relies on a 14-patient single-arm study, which may be viewed as limited evidence by regulators [news · published 2025-11-10].
- Uncertain operating capital needs — Cabaletta states it cannot estimate exact operating capital requirements due to numerous development risks [sec_mda · as of 2026-08-13].
- Net loss trend — Net loss of -$51.0M for the six months ended June 30, 2026 indicates ongoing cash burn [sec].
What to watch
- Initiation of the SSc registrational study in 4Q26 [sec · filed 2026-06-03].
- Topline data from the DM/ASyS registrational cohort expected mid-2027 [sec · filed 2026-06-03].
- BLA submission for rese-cel in myositis planned for 2H27 [news · published 2026-08-13].
- Initial data from the PC-free RESET-SLE cohort anticipated in the first half of 2026 [sec · filed 2026-05-04].
Sources: Catalysts · News · Pipeline · SEC filings · SEC MD&A · Generated October 13, 2026 · How we verify sources →
Run Cabaletta Bio, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Cabaletta Bio, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.22 · 0% dilution
Lead: Phase 2/Phase 3
3 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Financials
Short Interest
as of May 20, 2026- % of float
- 21.6%
- Days to cover
- 10.4
- Shares short
- 20,629,421
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
CABA short interestGovernance
Frequently asked questions
What is the AI investment thesis for Cabaletta Bio, Inc.?
Cabaletta Bio (CABA) is a publicly traded biotechnology company developing rese-cel, a CD19-directed CAR T-cell therapy for autoimmune diseases, with registrational programs in myositis and systemic sclerosis and a cash position of $225.1M as of June 30, 2026.
What is Cabaletta Bio, Inc.'s lead drug candidate?
Cabaletta Bio, Inc.'s most advanced tracked candidate is CABA-201 (Phase 2/Phase 3) for Systemic Sclerosis; Relapsing Multiple Sclerosis (RMS); Pemphigus Vulgaris.
Who is the CEO of Cabaletta Bio, Inc.?
Dr. Steven A. Nichtberger M.D. is the chief executive officer of Cabaletta Bio, Inc. (CABA).
Where is Cabaletta Bio, Inc. headquartered?
Cabaletta Bio, Inc. (CABA) is headquartered in Philadelphia, PA, United States.
What therapeutic areas does Cabaletta Bio, Inc. focus on?
Cabaletta Bio, Inc. develops therapies across Neurology, Immunology, Respiratory, Dermatology, Nephrology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.